Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

A report on long-term (up to 18 years) outcomes of a phase 1 clinical trial in which children with neuroblastoma were treated with Epstein–Barr virus-specific T lymphocytes and CD3-activated T cells. Of 11 patients with active disease at infusion, three achieved a complete response. This response was sustained in two patients—one for more than 18 years and the other for 8 years until the patient was lost to follow-up.